CervoMed Completes Phase 2 Enrollment of Neflamapimod in nfvPPA
CervoMed, BOSTON, July 9, 2026 CervoMed Inc. has announced the successful completion of enrollment in its Phase 2a clinical...
Frontotemporal Dementia
Advertisement
Grey Matters Receives First Brain-Dedicated PET Scanner
VANCOUVER, British Columbia, July 6, 2026 Grey Matters Health Inc. announced the delivery of its first FDA-cleared CareMiBrain™ brain-dedicated...
NKGen Biotech to Highlight Troculeucel Alzheimer’s Program at BIOCHINA Forum
SANTA ANA, Calif., July 2, 2026 NKGen Biotech announced that Chairman and Chief Executive Officer Paul Y. Song, M.D.,...
NanoDetection and Oligomerix Partner to Advance Tau-Based Neurodegenerative Diagnostics
FRANKLIN, Ohio & BRONX, N.Y., June 2026 NanoDetection Technology (NDT) and Oligomerix announced an exclusive worldwide licensing agreement granting...
AC Immune Reports Positive Phase 1 ALS Imaging Data for ACI-19626
LAUSANNE, Switzerland, May 22, 2026 AC Immune announced new preliminary Phase 1 data showing that its investigational TDP-43 PET...
Advertisements
Denali Therapeutics Regains DNL593 Rights for FTD
SOUTH SAN FRANCISCO, Calif., April 3, 2026 Denali Therapeutics Inc. announced it has regained full global rights to its...
Advertisement
